Pulmonary Neoplasms Clinical Trial
Official title:
Protocol for Radiofrequency Ablation of Pulmonary Neoplasms
NCT number | NCT00232128 |
Other study ID # | CCI LUN 02 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | October 3, 2005 |
Last updated | January 11, 2007 |
Start date | June 2003 |
Verified date | May 2006 |
Source | Oncology Specialties, Alabama |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This research trial involves the development of a new treatment for lung tumors. It is for patients whose tumor cannot be surgically removed, have refused surgery, or the tumor has not responded well to other forms of treatment. This treatment uses a needle probe to deliver energy into the lung tumor. This probe is placed utilizing a CT scan image. The energy heats the tumor causing tumor cell death.
Status | Terminated |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: The patients enrolled in this study should be judged to have
sufficient survival to benefit from control of local disease and include at least one of
the following: 1. unresectable primary or metastatic lung tumors 2. may benefit from multiple modalities of therapy 3. chemotherapeutic or radiation oncologic options have been exhausted Exclusion Criteria: 1. co-existing morbidities that preclude the use of surgery |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Comprehensive Cancer Institute | Huntsville | Alabama |
Lead Sponsor | Collaborator |
---|---|
Oncology Specialties, Alabama |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT05011890 -
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
|
N/A | |
Completed |
NCT00290953 -
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
|
Phase 2/Phase 3 | |
Completed |
NCT00132639 -
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Terminated |
NCT00241267 -
Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease
|
N/A | |
Terminated |
NCT02673021 -
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
|
N/A | |
Completed |
NCT00042679 -
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
|
Phase 2 | |
Not yet recruiting |
NCT05857995 -
Precision Lung Cancer Survivorship Care Intervention
|
N/A | |
Recruiting |
NCT04699188 -
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT02410603 -
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
|
||
Recruiting |
NCT02549638 -
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
|
||
Completed |
NCT02483052 -
RejuvenAir Lobectomy for Safety and Histology
|
Phase 1/Phase 2 | |
Completed |
NCT02370303 -
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
|
||
Completed |
NCT01470248 -
Study of Arsenic Trioxide in Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00922155 -
Diagnosis of Lung Lesions by Endobronchial Ultrasound With an Alternative Guide Sheath
|
N/A |